
VCHIP / CHAMP / VDH COVID-19 UPDATES



Wendy Davis, MD FAAP - Senior Faculty, Vermont Child Health Improvement Program, UVM Breena Holmes, MD FAAP – VCHIP Senior Faculty & Physician Advisor, MCH Division, VDH February 9, 2022










Please bear with us...

Technology Notes – "Welcome to Zoom!"

1) All participants will be muted upon joining the call.

₾ ::.

- **Presenters**: Please avoid the use of speakerphone and make sure your computer speaker is muted if you dialed in via phone.
- 3) To ask or respond to a question using the *Chat* box, click on your toolbar, type your question and press the *Enter* key on your keyboard to send.



- 4) If you have technology questions, please directly message Allison Koneczny, Angela Zinno or Ginny Cincotta.
- 5) Calls are RECORDED and posted on VCHIP web site for asynchronous review.





Overview

Celebrating Olympic stories!

- Jessie Diggins (Bronze medal, women's freestyle sprint)
- Ryan Cochran-Siegle (Silver medal, men's super-G)
- Welcome Astrid Lynae Nordgren (DOB 2/6/22 parents: biathlete Leif Nordgren & local NBC5 meteorologist Caitlin Napoleoni)
- □ Reminder weekly event schedule:
 - February VCHIP-VDH call calendar (see next slide); Gov. Media Briefings generally *Tuesdays only*; VMS calls with Dr. Levine 1st & 3rd Thursdays
- □ Practice Issues: COVID-19 Vaccine for 6m-4 yo VT
 Implementation
- □ Q & A/Discussion


[Please note: the COVID-19 situation continues to evolve – so the information we're providing today may change]





https://www.today.com/video/jessie-diggins-talks-history-making-medal-in-cross-country-skiing-individual-sprint-132685893769





VCHIP-VDH COVID-19 calls - 2022!

February calls – currently all Wednesdays:


- □ 2/2, 2/9, 2/16, 2/23/22
- We recognize that February school vacation weeks may affect your ability to participate!
- Continuing via Zoom!
- Schedule subject to change at any time if circumstances warrant!
- Please continue to send your feedback re: schedule/topics to vchip.champ@med.uvm.edu
- □ VMS calls w/VDH Comm. Levine now 1st/3rd Thursdays





And now for something completely different...

In the spirit of continuous quality improvement, we are continuing our **NEW CALL FORMAT** – our own PDSA cycle



- Responding to your comments and feedback thank you!
 - Desire to be able to focus on content but not miss Q & A from chat; avoid duplication of responses that may be included in presentation
- □ Content presentation for ~20-25 minutes
- Chat will be monitored, BUT both verbal and written feedback will occur *AFTER* the presentation
- REMINDER: Chat Q & A is (re)organized, streamlined and made available following the call each day.





VMS COVID Convos with Health Commissioner Levine

- New Schedule for 2022
- Calls with VDH Commissioner Levine now 1st and 3rd Thursdays
- Next VMS COVID Convo with VDH Commissioner Levine is 2/17/21
- Summary: VMS calls are held the first and third Thursdays of the month from
 12:30 to 1:00 p.m.
 - Join Zoom Meeting: https://us02web.zoom.us/j/86726253105?pwd=VkVuNTJ1ZFQ2R3diSVdqdlJ2ZG4yQT09
 - Meeting ID: 867 2625 3105 Password: 540684 Dial In: 1-646-876-9923








VDH Web Site: Sign of the Times?

- New look to VDH home page:
 COVID-19 now occupies top spot on sidebar (previously on navigation bar at top of page)
- COVID-19 Vaccine still on navigation bar















PROFESSION

MEMBERS

Child care providers help make sure Vermont's children are safe and healthy. Find health information, resources and requirements especially for child care providers.

Read More ①

USEFUL RESOURCES

INFANT SAFE SLEEP

LEAD TESTING IN DRINKING WATER - WHAT CHILD CARE PROVIDERS NEED TO DO





Situation update

New Cases

497

108,166 Total

Currently Hospitalized

93

Hospitalized in ICU

24

Percent Positive 7-day Avg.

8.1%

New Tests

9,611

3,271,397 Total

Deaths


562

0.5% of Cases

Last Updated: 2/9/2022, 11:05:53 AM



Confirmed Cases, Probable Cases, Recoveries and Deaths



Note: Starting Feb. 5, case dashboard will not be updated on Sat/Sun or holidays. Breakdown of the previous days' cases will be reported Mon. or day following a holiday. The Case Dashboard is M-F, typically by 1 pm.


Case information reflects counts as of the end of the previous weekday. All data are compiled by the Health Department and are preliminary and subject to change.

https://www.healthvermont.gov/covid-19/current-activity/vermont-dashboard

- One year ago: 13,105 **VT** total cases; 59 new/53 hosp.
- U.S. **75.2** million+ cases; **889,522** deaths
 - https://www.nytimes.com/interactive/2021/us/covidcases.html (updated 2/9/22)
- Past week: av. 253,782 cases/day (14d. change -62%)
- 5.76 million+ deaths worldwide; 400.7 million+ cases (+26% & -22% 14-day change respectively)
- VDH Data Summary now q.o.week. 2/3/22: NO Weekly Spotlight topic
 - Table of Contents: Overview of COVID-19 in Vermont; Clinical Course; Vaccine Breakthrough.
 - Vaccine breakthrough cases = 37,561 since Jan. 2021 (~7.9% of fully vaccinated). Find previous summaries at: https://www.healthvermont.gov/sites/default/files/documents/pdf/COVID19-Weekly-Data-Summary-2-3-2022.pdf



Situation update










COVID-19 Pediatric Cases

Feb 7, 2022

This brief reflects data as of February 5, 2022 (the last complete MMWR week). All rates are calculated per 10,000 people. Data is preliminary and subject to change.


Number of Cases by Week







COVID-19 Pediatric Cases







Vermont Educational COVID-19 Data

- NOTE: VT AOE has ceased data collection for "COVID-19 Cases in VT K-12 Learning Communities While Infectious"
 - Find previous files at:


https://www.healthvermont.gov/sites/default/files/documents/pdf/COVID19-Transmission-Schools.pdf

- VT College & University dashboards:
 - **UVM update** (week of 1/31/-2/6/22): 41 pos. tests off campus; 34 on campus; 3 faculty; 4 staff.
 - Bennington College (as of 2/7/22): 1 total active/0 new active cases.
 - Middlebury College (as of 2/7/22): 57 new cases; 35 total active (35 students/0 employees)





Fig 6. United States: Number of Child COVID-19 Cases Added in Past Week*



Week ending in

"Note: 5 states changed their definition of child cases: AL as of \$113/20, NI as of \$12/20, RI as of \$13/20, RI as of \$12/20, WI as of \$12/20 (WI as of \$12/20

TX previously reported age for only a small proportion of total cases each week (eg. 2-20%); these cumulative cases through \$/25/21 are included (7,754). Due to evallable data and changes made to dashboard. AL cumulative cases through 7/29/21.

Due to available data and calculations required to obtain MA child cases, weekly estimates fluctuate

On 2/3/22, Nil cumulative child cases and total cases through 1/13/22

As of 3/3/22, NE cases by age are again available and included for 6/24/21 through 3/3/22, resulting in an increase of 53,569 child cases and 2/20,469 total cases. See detail in Appendix: Data from 49 states, NYC, DC, PR and GU

All date reported by state-local health departments are preliminary and subject to change: Analysis by American Academy of Pediatrics and Children's Hospital Association

https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/







Fig 7. United States: Child COVID-19 Cases Added in Past Week, by Region*



Week ending in

5 states changed their definition of child cases: AL as of \$13/20, HI as of \$27/20, RI as of \$110/20, MO as of 101/20, WV as of \$112/21

On 1/1422 TX released new date that is NOT included in cumulative case counts or floures but located here and in Appendix 26 of this report /774.063 cumulative child cases as of 1/20/22:

TX previously reported age for only a small proportion of total cases each week (eg. 2-20%); these cumulative cases through 8/25/21 are included (7,754). Due to available data and changes made to dashboard, AL cumulative cases through 7/29/21

Due to available data and calculations required to obtain MA child cases, weekly estimates fluctuate

On 2/3/22, HI cumulative child cases and total cases through 1/13/22

As of 3/3/22, NE cases by age are again available and included for 6/34/31 through 3/3/22, resulting in an increase of 53,069 child cases and 220,489 total cases. See detail in Appendix: Data from 49 states, MYC, DC, PR and GU

All data reported by state/local health departments are preliminary and subject to change; Analysis by American Academy of Pediatrics and Children's Hospital Association


https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/





^{*} Note: Regions are the US Census Regions

Fig 8. United States: Number of COVID-19 Cases Added in Past Week for Children and Adults*



On 1/14/22, TX released new data that is NOT included in cumulative case counts or figures but located here and in Appendix 3B of this report (774.082 cumulative child cases as of 1/20/22):

TX previously reported age for only a small proportion of total cases each week (eg. 2-20%); these cumulative cases through \$/25/21 are included (7,754). Due to available data and changes made to dashboard, AL cumulative cases through 7/29/21

Note: 5 states changed their definition of child cases: AL as of 8/13/20, MI as of 8/27/20, RI as of 9/10/20, MO as of 10/1/20, WV as of 8/13/21;

Due to available data and calculations required to obtain MA child cases, weekly estimates fluctuate

On 2/3/22, HI cumulative child cause and total cause through 1/13/22.

As of 2/3/22, NE cases by age are again available and included for 6/34/31 through 3/3/22, resulting in an increase of 53,069 child cases and 250,469 total cases. See detail in Appendix: Data from 49 states, NYC, DC, PR and GU

https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19infections/children-and-covid-19-state-level-data-report/





VDH COVID-19 Vaccine Registration & Sites

GETTING THE COVID-19 VACCINE

Find out about vaccines for children ages 5 to 11 3

GET THE MOST PROTECTION WITH A BOOSTER SHOT!


You should get a booster if you are 12 or older and you received:

- · your Johnson & Johnson vaccine at least two months ago or
- · your second dose of Pfizer or Moderna vaccine at least five months ago

If you are age 18 or older, your booster can be the vaccine type of your choice: Pfizer, Moderna or Johnson & Johnson, no matter which vaccine you got originally. For youth 12 - 17 the booster must be Pfizer.


See Frequently Asked Questions about boosters (3)


WHERE TO GET YOUR BOOSTER SHOT, FIRST OR SECOND DOSE



VDH COVID-19 Vaccine Dashboard ("Overall" view: 2/8/22)

- Daily updates Tuesday thru Sat.
- Data = counts reported by end previous day; subject to change.
- https://www.healthvermont.gov/covid-19/ vaccine/ covid-19-vaccinedashboard
- Notes: Vermont Forward percentages use data from CDC, which includes some data not reported to VDH; these estimates may differ from those reported elsewhere in the dashboard.






Updated 02/08/2022 12:09 PM





VDH COVID-19 Vaccine Dashboard ("Statewide" view)

- Daily updates Tuesday thru Saturday
- Data = counts reported by end prev. day; subject to change.
- https://www.healthvermont.gov/ covid-19/ vaccine/ covid-19vaccine-dashboard
- □ By Age Statewide (≥ 1 dose):
 - □ 5-11 = 60% (59% on 2/1/22)
 - □ 12-17 = 77% (76% on 2/1/22)
 - 18-29 = 70% (69% on 2/1/22)
 - **VT Age 5+ = 87%** (87% on 2/1/22)








Proportion of Eligible
US Children Ages 12-17
Who Received the
Initial Dose of the
COVID-19 Vaccine, by
State of Residence

Source: AAP analysis of data series titled "COVID -19 Vaccinations in the United States, Jurisdiction". CDC COVID -19 Data Tracker (URL:

https://data.cdc.gov/Vaccinations/COVI D-19-Vaccinations-in-the-United-States-Jurisdi/unsk-b7fc). ~ Age information was provided with Idaho data since 1.25.2022. Inclusion of this information added 67K initial dose recipients to the 12-17 group as of 2.2.2022. Check state web sites for additional or more recent information.



39%

94%

Received Initial Dose


as of 2.2.2022

Proportion of Eligible
US Children Ages 5-11
Who Received the
Initial Dose of the

COVID-19 Vaccine, by

State of Residence

Source: AAP analysis of data series titled "COVID -19 Vaccinations in the United States, Jurisdiction". CDC COVID -19 Data Tracker (URL: https://data.cdc.gov/Vaccinations/C OVID-19-Vaccinations-in-the-United-States-Jurisdi/unsk-b7fc). ~ Age information was provided with Idaho data since 1.25.2022. Inclusion of this information added 31K initial-dose recipients to the 5-11 age group. Check state web sites for additional or more recent information.



13%


63%

Received Initial Dose

as of 2.2.2022~

From the CDC Vaccine Tracker

Total Doses Administered Reported to the CDC by State/Territory and for Select Federal Entities per 100,000 of the Total Population



Daily Change in Number of COVID-19 Vaccinations in the United States Reported to CDC

7-Day moving average



https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html





From the CDC: SARS-CoV-2 Variants in the U.S.




Note: week-to-week comparison in Omicron variant proportion (purple): far right bar in graph on left is week ending 2/5/22 LIGHT PURPLE is Omicron subvariant BA.2.





From the CDC: SARS-CoV-2 Variants in the U.S.



Note: week-to-week comparison in Omicron variant proportion (purple). Map on left is week ending 2/5/22. Note emergence of Omicron subvariant BA.2 (LIGHT PURPLE) in map on left.






Don't Forget Influenza!

- Current Influenza-like Illness (ILI) activity level remains MINIMAL in Vermont
- 5 pediatric flu deaths this season
 - U.S. flu activity decreasing in recent wks. but remains elevated above baseline activity. While influenza activity is difficult to predict, the CDC expects it to continue for several more weeks.
 - Majority = influenza A(H3N2)
- Link to weekly surveillance:

Syndromic Surveillance

Vermont Emergency Room and Urgent Care Visits for Influenza-like Illness or Diagnosed Influenza



Iness. The 2021-22 season's ILI data are not directly comparable to previous seasons

https://www.healthvermont.gov/sites/default/files/documents/pdf/2021-2022-Flu-

WeeklyReport-Week-03.pdf





AAP (National) Updates

Slides 26 – 37 courtesy of the American Academy of Pediatrics – from today's

Chapter Chat (2/9/22)

Slides 28-37 added after today's call






Next COVID-19 Town Hall

- Next Town Hall Thursday, February 17, 2022 8 pm Eastern
- Session will address the latest related to the COVID-19 pandemic and its impact on children, adolescents, and families – hear from leading experts and connect with your peers
- Expert panelists to include COID/vaccine experts
- Find previous recordings on AAP COVID-19 Town Hall webpage:

https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/connecting-with-the-experts/



AAP Interim Guidance Updates




Recently Released

- Return to Sports
- Safe Schools
- Caring for
 Patients During
 Episodes of Surge

In Revision

- Testing
- Therapeutics
- Acute Illness



Report posted Mondays on AAP.org







NYT 2.9.22 all ages

As of 2/03/22 – 12,042,870 cumulative confirmed child COVID-19 cases

- In the past week over 630,000 cases were reported
- Down from the 1.1 million cases reported the week ending January 20th;
 but over double the peak level of the Delta surge in 2021
- An increase of roughly 1.4 million new cases in the past 2 weeks


Trends in Hospital-reported Counts of Past-week Confirmed and Suspected COVID-19 Pediatric Admissions by US Census Region Through 2.8.22

Source: AAP analysis of COVID-19 pediatric admissions based on the "COVID-19 Reported Patient Impact and Hospital Capacity by State Timeseries" published by the U.S. Department of Health & Human Services.



Number of Past-week Confirmed and Suspected COVID-19 Pediatric Hospital Admissions, 50 States and District of Columbia, by Week


9.1.2020 - 2.8.2022



Source: AAP analysis of COVID-19 pediatric admissions based on the "COVID-19 Reported Patient Impact and Hospital Capacity by State Timeseries" published by the U.S. Department of Health & Human Services.

Number of Past-week Confirmed and Suspected COVID-19 Pediatric Hospital Admissions, by Census Region by Week

9.1.2020 - 2.8.2022



Source: AAP analysis of COVID-19 pediatric admissions based on the "COVID-19 Reported Patient Impact and Hospital Capacity by State Timeseries" published by the U.S. Department of Health & Human Services. Child populations (ages 0-17) are based on 2020 population projections published by the US Census Bureau (URL: https://www.census.gov/programs-surveys/popest/technical-documentation/research/evaluation-estimates/2020-evaluation-estimates/2010s-state-detail.html)

February 4 ACIP Meeting

- Voted on the BLA approved Moderna Spikevax for persons > 18 years of age
- Discussion about risk of myocarditis/pericarditis and question about increasing interval between Dose 1 and Dose 2 of mRNA vaccine to 8 weeks.
 - Canadian data showed decreased cases of myocarditis/pericarditis with longer interval (> 8 weeks)
 - Longer interval may also increase immunogenicity and vaccine effectiveness
 - No vote, but likely to be discussed at a future meeting

Updates to CDC Clinical Considerations for COVID Vaccines

- Also discussed during February 4 ACIP Meeting
- Modify Emergency Use Instructions for moderately to severely immunocompromised people:
 - Shorter booster interval after mRNA primary series from 5 months to 3 months
 - Additional dose of mRNA vaccine 28 days after a Janssen primary dose, then a booster dose at least 2 months after additional dose (any COVID vaccine, but preference for mRNA)
 - Revaccination for certain sub-groups (Recipients of HCT, CAR-T-cell, or other B-cell depleting therapies who received doses of COVID-19 vaccine prior to or during treatment should be revaccinated for doses received before or during treatment.)
 - Case-by-case clinical decision making

COVID-19 Vaccine Updates

- FDA VRBPAC meeting on February 15 to discuss EUA of the Pfizer-BioNTech COVID-19 vaccine in 6 months - 4 year olds
- ACIP meeting on February 17
- Need to review data
- <u>CDC Operational Planning Guide for 6 months 4 years</u> recently released
 - 6 month 4 year product will be maroon cap and similar
 storage/handling requirements as purple cap product for 5-11 yo



Information for Families

New and updated articles on HealthyChildren.org

- How to Talk to Your Child about Their Positive COVID-19 Test
- <u>COVID-19 Testing and Kids: What</u> you Should Know
- COVID Vaccine Checklist for Kids Age 5-11
- Are there shortages of infant formula due to COVID-19?

New printable flyer, available on the COVID-19 toolkit:

Protecting your child with the COVID-19 vaccine

The American Academy of Pediatrics recommends COVID-19 vaccines for all eligible children 5 years and older.

Millions of kids and teens already have been safely vaccinated.



AAP Advocacy on COVID Therapeutics for Children

- Letter to ASPR last week raising concerns that "children, especially children younger than 12, lag dangerously behind adults for COVID-19 therapeutic treatment options.
- Calls for:
 - Inclusion of children in trials for therapeutics
 - Interagency approach to making more options for children available

American Academy of Pediatrics

AAP Headquarters 345 Park Blvd Itasca, II. 60143 Phone: 630/626-6000 Fax: 847/434-8000

Reply to AAP Washington Office 601 13th St NW, Suite 400 Washington, DC 20005 Phone: 202/347-8600 E-mail: kidstst@uap.org

President Moira A. Szilagyi, MD, FAA

President-Elect Sandy L. Chung, MD, FAAP Immediate Past President Lee Savio Beers, MD, FAAP

Dennis M. Cooley, MD, FAAP

CEO/Executive Vice President
Mark Del Monte, JD

Board of Directors District I

Wendy S. Davis, MD, FAAP
District II

District III
Margaret C. Fisher, MD, FAAP

District V Jeannette "Lia" Gaggino, MD, FA District VI

District VII Gary W. Floyd, MD, FAAP

Martha C. Middlemist, MD, FAAF Dietrict IX

Yasuko Fukuda, MD, FAAP

District X

Madeline M Joseph MD, FAAP

At Large Charles G. Macias, MD, FAAF

At Large Joseph L. Wright, MD, FAAP February 4, 2022

The Honorable Dawn O'Connell
Assistant Secretary for Preparedness and Respons
200 Independence Avenue, S.W.
Washington, D.C. 20201

Dear Ms. O'Connell

On behalf of the American Academy of Pediatrics (AAP), a non-profit professional organization of 67,000 primary care pediatricinase, pediatric medical sub-specialists, and pediatric surgical specialists dedicated to the health, safety, and well-being of infants, children, adolescents, and young adults, I write to urge the Assistant Secretary for Preparedness and Response (ASPR) to coordinate and enhance efforts to make more therapeutics available for children, including infants and young children, to treat COVID-19. While we are placed to see the most recent Therapency Use Authorization (EUA) announcement for remdesivir, children, specially children younger than 12, lag dangerously behind adults for COVID-19 therapeutic treatment options.

Pediatricians and the families they care for were overjoyed when the Food and Drug Administration (FDA) granted emergency use authorization of the Pfizer-BioNTech vaccine down to age five and are anxiously awaiting approval for children under five. While we are comforted that many children are now able to benefit from the protection of vaccination against COVID-ye, we are oncerned that recently developed COVID-ye infections in children, especially children with pre-existing conditions placing them at higher risk for complications, and we urge your generics to urgently at on this need.

Children have been greatly affected by the COVID-19 pandemic. Reported COVID-19 cases among children have spiked dramatically across the United States during the Omicron variant surge. The ASP and the Children's 14 hospital Association have been tracking COVID cases in children since the start of the pandemic. Child cases are continuing to Tox, for the week ending January 20°, nearly 1,15,000 child COVID-19 cases were reported—nearly five times the rate of the peak of last whinter's surge. Over, 10°, million children have tested positive for COVID-19 since the onset of the paak of last whiter's surge. Over, 10°, million children have tested positive for COVID-19 cases were reported; and millions of children have the conset of the paak of last whiter's surge. Over, 139° children have the office of COVID Since the start of pandemic and millions of children have been negatively impacted by missed schooling, social isolation, and in too many cases, the death of parents and other caregivers. 1

Simply stated, the highly transmittable Omicron variant has created a new and pressing risk to children and adolescents across this country. With the dramatic increase in child case, and as ubsequent hospitalizations, it is counter to the ethical principle of distributive justice to allow children to take on great burdens during this pandemic but not have access to therapeutics that treat COVID-19. While FDA has authorized two oral antivirals, Pfizer's Paskovid and Merck's molnupiratin, for the treatment of COVID-19 or certain patients and COVID-19 monoclonal antibody therapeutics (mAb) are available for people ages 12 years or older, the majority of children are not able to benefit from these treatments that can reduce the severity of a COVID-19 infection, prevent hospitalizations, and decrease the risk of long-term disability and death.

AAP strongly urges the federal government to work to ensure that children under 12 have access to COVID-19 therapeutics. Children must be included in trials for COVID-19 therapeutics to best understand optimal dosing recommendations and any potential unique immune responses and/or unique safety concerns. Questions about unknown safety concerns will not be answered by posing questions, but only through carefully designed trials which include children. For these reasons, we urge the inclusion of children in trials as we move forward in the development of future therapeutics.

Children account for twenty-five percent of the population and their unique vulnerabilities along with their physiologic and developmental differences mean that preparedness and response efforts should account for their distinct needs. Significant strides have been made over the past ten to fifteen years to develop medical countermeasures (MCMs) to address potential disaster hazards, including chemical, biological, radiologic, and nuclear threats. Yet, major gaps still remain related to MCMs for children, a population highly vulnerable to the effects of exposure to such threats, because of their physiologic and developmental differences from adults. "Many vaccines and pharmaceuticals approved for use by adults as MCMs do not yet have pediatric formulations, dosing information, instructions for use, safely information, or efficacy data.

Children are not little adults and the factors that must be considered when planning for children may differ when considering the care needs of infants versus preschool-aged children versus adolescents. Drugs work differently in children than in adults and must be studied specifically for their use. New tests, treatments, and vaccines must all be tested in the pediatric population to ensure their safety and efficacy for use in children. These therapies must also be appropriate for different ages and stages of development. It is also vitally important that the population studied reflect the racial and ethnic diversity of the U.S. population, and not exclude populations at risk that may greatly benefit from COVID-19 the represents.

ASPR is uniquely positioned to ensure adequate development and procurement of COVID-9 medical countermeasures for children. In the recent past, the Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) established the Pediatric and Obstetric Integrated Program Team (Peds08-IP) to assist HHS with strategies for identifying, developing, acquiring, deploying, and using high priority medical products for children and pregnant women in all public health emergencies. We would urge you to consider a similar interagency approach to making more COVID-19 therapeutic options for children available. It is essential that more attention and priority be paid to COVID-19 therapeutic options for children available.

Thank you for your attention to this important matter. We look forward to working with you to ensure children have access to therapeutics designed to treat COVID-19. If we can be of further assistance, please contact Tamar Magarik Haro at than @baap.org.

Sincerely,

Moira Spagyimo

Moira Szilagyi, MD, PhD, FAAP President

CC:

Jeff Zients, White House Coronavirus Response Coordinator Janet Woodcock, Acting Commissioner, Food and Drug Administration Rochelle Walensky, Director, Centers for Disease Control and Prevention

WEBINAR ANNOUNCEMENT: MEDICAID REDETERMINATIONS AT THE END OF THE PUBLIC HEALTH EMERGENCY (PHE)

Special Guest:

Tricia Brooks, MBA

Research Professor, Georgetown Center for Children and Families Commissioner, Medicaid and CHIP Payment and Access Commission

Tuesday, February 15, 2022

3:30pm-4:30pm Central

Registration in Chat!





VT Clinicians in the News

- From Kaiser Health News: In Super-Vaxxed Vermont, Covid strikes – but packs far less punch. Featuring Drs. Rebecca Bell, Trey Dobson, Tim Lahey, Ben Lee
 - Dr. Bell: "I have to remind people that cases don't mean disease, and I think we're seeing that in Vermont...We have a lot of cases, but we're not seeing a lot of severe disease and hospitalization...I have not admitted a vaccinated child to the hospital with covid."
 - Dr. Lee: "It's something beyond just the size...There is a sense of communal responsibility here that is a bit unique."
 - https://khn.org/news/article/in-super-vaxxed-vermont-covid-strikes-but-packs-far-less-punch/
 - https://www.burlingtonfreepress.com/story/news/2022/02/01/post-pandemic-vermont-could-model-living-covid/9296200002/





VT Clinicians in the News (cont'd.)

NEW this evening – WCAX News:

"COVID vaccinations for youngest kids could help stressed families"

Featuring Becca Bell, MD FAAP

https://www.wcax.com/2022/02/09/covid-vaccinations-youngest-kids-could-help-stressed-families







(Pediatric) COVID-19 Issues in the News

New Omicron subvariant BA.2

Spreading rapidly in parts of Asia & Europe; now dominant in Denmark. Impact/potential for surge TBD? https://www.nytimes.com/2022/02/07/world/europe/omicron-subvariant-ba-2.html

Masking requirements

- Recent news of states dropping school mask mandates: MA (2/28), NJ, CT, DE, OR, (?)
 IL; NY & CA considering
 - https://www.npr.org/2022/02/09/1079456073/states-are-ending-mask-mandates-is-that-a-good-idea-for-school-students
 - https://www.nytimes.com/2022/02/08/briefing/mask-mandates-covid-new-jersey.html?searchResultPosition=1
 - https://www.nytimes.com/2022/02/08/health/covid-mask-restrictions.html

COVID-19 Vaccine for younger children: not without controversy (AAP natl. response)

https://www.aap.org/en/news-room/news-releases/aap/2021/american-academy-of-pediatrics-statement-on-covid-19-vaccine-for-children-under-5/



NEW COVID-19 Resources from VDH & VT AOE

VDH Health Advisory:

□ https://www.healthvermont.gov/sites/default/files/documents/pdf/ HAN-Prioritizing-Patients-for-CV-19-Therapeutics.pdf

From Vermont AOE

 https://education.vermont.gov/documents/covid19-jan-2020protocol-flowchart

Thank you, Kaitlyn Kodzis! (VT State School Nurse Consultant)





VT Immunization Advisory Council Meeting (2/8/22)

Vermont Statutes Online:

DEPARTMENT OF HEALTH

https://legislature.vermont.gov/statutes/section/18/021/01131; Title 18: Health, Ch.

021 : Communicable Diseases; Subch. 004 : Immunization (Cite as: 18 V.S.A. § 1131)

- § 1131. Vermont Immunization Advisory Council
 - (a) ...created...for the purpose of providing education policy, medical, & epidemiological expertise & advice to VDH re: IZ safety/schedules.
 - (b) Membership: rep of VT BMP (appointed by Gov.); Secys. AHS & Education or designees; State epidemiologist; practicing pediatrician (appointed by Gov.); reps of public & independent schools, appointed by the Governor; any others deemed necessary by the Commissioner.
 - (c) Powers/duties: review/make recs. re: IZ schedule school/child care attendance;
 provide any other advice requested by VDH Commissioner.
 - (e) Meetings: no < once/yr.; select chair from among members at the first meeting.
 Majority constitutes quorum.

VT Immunization Advisory Council Meeting (cont'd.)

Vermont Statutes Online:

https://legislature.vermont.gov/statutes/section/18/021/01131; Title 18: Health, Ch. 021: Communicable Diseases; Subchapter 004: Immunization (Cite as: 18 V.S.A. § 1131)

- Meeting February 8, 2022
- Moderated by AOE Secretary French: "organizational meeting."
- Membership & categories of representation in process of being confirmed.
- □ The need to discuss the role of COVID-19 vaccine by the Council was referenced but not fully discussed; no action considered or taken.






Coming Soon! Vermont Medical Society – February is Advocacy Month

2022 Virtual Health Care Policy Town Hall

- Monday, February 14, 12 1 pm
- Join VT legislative leaders: Senate Pres Pro Tem Becca Balint; House Speaker Jill Krowinski; Sen. Health & Welfare Comm. Chair Ginny Lyons; House Human Services Comm. Chair Ann Pugh; House Health Care Comm. Chair Bill Lippert
- Share insights re: current health policy issues in pandemic context; apply your medical expertise to help lead evidence-based health care policy change in Vermont..
- Via Zoom (no registration required) see tonight's email or https://vtmd.org/vms-2022advocacy-daymonth/







Coming Soon! Vermont Medical Society

- 2022 Virtual Congressional Town Hall
- □ Thursday, March 3, 12:30 − 1:30 pm
- Lead the VMS conversation on federal health policy with representation from the offices of:
 - Senator Patrick Leahy; Senator Bernie Sanders; Representative Peter Welch
- Via Zoom (no registration required):
 https://vtmd.org/vms-2022-advocacy-daymonth/







From the Vermont Medical Society Legislative Update

Bills in motion

- Prop 5: approved by Vermont House on 2/8/22; sending the question of whether to amend the state Constitution to guarantee sexual and reproductive freedoms to voters come November. The vote was 107-41.
- FY22 Budget Adjustment: includes an increase to Medicaid reimbursement rates through their alignment with the Medicare RBRVS.
- S.74, Patient End of Life Choices bill
- H.654, COVID-19 Flexibilities: extend regulatory COVID-19 flexibilities until 3/31/23. Passed House & now in Senate Health & Welfare Committee.
- S.30: Prohibits Firearms in Hospitals: This bill passed both the House and Senate and will head to the Governor's desk.





From the Vermont Medical Society Legislative Update (cont'd.)

Bills in motion

- H. 655, a bill to establish a telehealth licensure and registration system:
 Passed out of committee by House Health Care.
- Mental Health legislation aimed at preventing emergency department wait times: Stephanie Winters testified last week in Senate Health and Welfare Committee on several mental health bills.
- <u>H.548</u>, miscellaneous cannabis bill: aimed at removing THC potency limits was (House Judiciary Committee). Jill Sudhoff-Guerin testified against.
- S.244, aimed at strengthening primary care comprehensively by raising reimbursement, increasing overall spend on primary care & providing parity reimbursement for audio-only telehealth services. VMS, AAPVT & VTAFP will testify at Senate Health and Welfare Committee hearing.





Tuesday Media Briefing (2/8/22)



Governor Phil Scott

- Congrats RCS on silver medal: bib #14 14th state. Thanks the whole family for continuing to inspire us.
- COVID trends moving in right direction not much to add.
- Working w/Legislature re: 51m. (ARPA capital funds) proposal to expand wireless & cell service across VT "time to bring VT into the 21st century"; benefits economic development & public safety for VTers and tourists.







VT Dept. of Public Service Commissioner June Tierney

- Planning for 100 new cell towers in VT; expansion mobile & wireless.
- Will impact public safety, transportation, education, the economy. "Fundamentally about equity, as well."
- Have and will conduct drive tests to identify/confirm gaps.
- Anticipate robust community engagement process for tower sites prior to site selection. "Respect for the will of communities will be the north star of planning process."
- □ Public safety data: most e911 are from cell phones. 75% in 2021 were from mobile wireless. 14% are abandoned presumably b/c service dropped.







VT AHS Interim Secretary Jenney Samuelson

- Pandemic has exposed gaps in our care system. This week helping to make MH & other care/services more available to VTers. The need to deliver care remotely during the pandemic exposed lack of universal hiquality cell service.
- Governor's proposal to improve cell service & wireless access is key for AHS clients/staff.
- Hospital bed availability stable & less staff absent. VT hospitals experienced serious stress but did better than elsewhere in U.S.
- Today 58% 12+ UTD on vax. We recognize it can be hard to plan to get an additional dose – want to make vaccines easy/accessible.





PHIL SCOTT 1975 SANDER STANDARD STANDAR

VT AOE Secretary Dan French

- More stability in school operations
- Important to continue to make progress with vaccine coverage.
- Reaching stability in both supply/demand for Test at Home kit availability.
- This week independent schools are now included and can place orders for test kits.
- Working on Assurance Testing Program for school staff in response to requests when we announced conclusion of surveillance testing.
 - Will provide 2 tests/staff member/week to provide assurance. Kits will be distributed to school districts and participation will be entirely voluntary. Hope to launch soon.







VT DFR Commissioner Mike Pieciak

- Trends in VT have continued to improve: 7d.average <400 cases/day. Down 41% this week & 79% since mid-January peak.
- Testing down this week; case decreases outpacing testing decrease. May not be capturing all at-home tests.
- Also decrease in LTCF outbreaks & college campus cases.
- □ U.S. cases declining: 46% for the nation; 39% in New England.
- Forecast for VT: cont'd. case decrease thru February into March. May still see 100-200 cases/day but improvement will continue.
- □ Fatalities: total = 558; 13 to date in February.







VDH Commissioner Mark Levine:

- "As Omicron subsides, it's reasonable to look ahead at future of COVID with hope. Just a year ago, many of us had little-no defense against virus & were eagerly awaiting our turn for vaccine." Virus has changed but power of vax still strong; we've learned a lot re: evolving virus & protection.
- Being vaccinated means UTD w/booster.
- Real-time data demonstrates higher protection against serious illness, hosp., d.
 Impact across all ages & health status.
- Our rates help keep VTers protected & out of hospital better positioned to meet whatever the virus might present us with in the near or not-distant future.
 For those not vaccinated, I don't believe it's skepticism but time/convenience – and we still have vaccine clinics around the state.







VDH Commissioner Mark Levine:

- □ If you've gotten your booster, please help spread the word to friends & family
- □ ~64% PCPs in VT are administering vaccine.
- Health care system has been huge key to our vaccine success.
- In closing, amount of virus may be going down, but Omicron still here & still very contagious.
- "We know the virus is not going away. But vaccine & boosters can help protect us all."











Practice Issues: Vermont Department of Health – Immunization Program

Monica Ogelby, MSN, RN – Immunization Program Manager Merideth Plumpton, RN - Nurse Program Coordinator



COVID-19 vaccine for those 6 months through 4 years - Vermont implementation

- ~26,000 total patients in this age group
- Medical homes will be the primary vaccinators
 - Pharmacies can only vaccinate age 3 and older, and few are participating for these ages
 - Community clinics are going to be very limited
 - Offices of Local Health will focus on vaccinating WIC participants and families and will conduct equity clinics. WIC families accounts for ~8,000 individuals in this age range.
 - See 02.08.2022 memo: <u>www.healthvermont.gov/sites/default/files/documents/pdf/HS-IZ-Memo-02.07.22-Provider-Preparation-6m-4y-COVID19-Vaccine.pdf</u>

COVID-19 vaccine for those 6 months through 4 years -Timeline

- VRPAC scheduled on 2/15: www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-advisory-committee-meeting-discuss-request-authorization-pfizer
- ACIP will likely meet 02/17. This is not yet scheduled.
- Resources for vaccine are not available until EUA approval.
- Immunization Program will host a training 02/18, pending ACIP vote.
- Ordering of this vaccine starts TODAY (by 3pm)
 - There will be the opportunity to order next week (02/16), though vaccine will arrive around the same time.
 - If at all possible, PLEASE place your initial orders TODAY. It helps with planning. Your practice will know how much vaccine it will receive and when by the end of this week.

COVID-19 Vaccine for those 6 months through 4 years-Ordering Guidance (Maroon cap)

- Maroon Cap will be available in VIMS today
- 10 doses per vial / 100 dose (or multiples of 100 doses) minimum direct shipment
- Orders today from the distributor may be delivered as early as 2/21
 - 2/21 is a Federal Holiday you must be able to receive vaccine on 2/21 if ordering from the distributor this week
 - Please note in VIMS practice comments in VIMS if you will be closed/cannot receive vaccine on 2/21
- You can order less than 100 doses!
 - Orders of less than 100 doses will be delivered by our vaccine depot beginning on the week of 2/28
 - Direct distributor shipments are preferred/encouraged for practices that can accommodate 100 dose minimum orders
- Please order what you anticipate administering within two weeks of receiving the vaccine.
- Depending on the statewide volume of vaccine requests, the distribution team may reach out to increase or decrease your order size depending on supply availability
- Current COVID-19 Vaccine Ordering Guidance now available online:

www.healthvermont.gov/sites/default/files/documents/pdf/HS-IZ-emailed-COVID19-Ordering-Guidance.pdf

Pfizer-BioNTech COVID-19 Vaccine Products

PRELIMINARY – SUBJECT TO CHANGE PENDING REGULATORY GUIDANCE AND AUTHORIZATION/APPROVAL; CDC DOCUMENT – SHARED FOR JURISDICTIONAL PLANNING PURPOSES ONLY

	Current P	roducts	Future Product	
Age Indications ^a	12 years and older	5 through 11 years	6 months through 4 years	
Vial Cap Color and Label with Color Border	GRAY 📳	ORANGE	MAROON	
Preparation	Do Not Dilute	Dilute Before Use	Dilute Before Use	
Amount of Diluent Needed per Vial ^b	Do Not Dilute	1.3 mL	2.2 mL	
Dose Volume/Dose	0.3 mL/ 30 mcg	0.2 mL/ 10 mcg	0.2 mL/ 3 mcg	
Doses per Vial	6 doses per vial	10 doses per vial (after dilution)	10 doses per vial (after dilution)	
Storage Conditions				
ULT Freezer (-90°C to -60°C) ^c	9 months	9 months	9 months	
Freezer (-25°C to -15°C)	DO NOT STORE	DO NOT STORE	DO NOT STORE	
Refrigerator (2°C to 8°C)	10 weeks	10 weeks	10 weeks	
Room Temperature (8°C to 25°C)	12 hours prior to first puncture (including any thaw time)	12 hours prior to first puncture (including any thaw time)	12 hours prior to first puncture (including any thaw time)	
After First Puncture (2°C to 25°C)	Discard after 12 hours	Discard after 12 hours	Discard after 12 hours	

^a Use the appropriate product based on the age of the recipient.

Pfizer website will have updated chart once EUA is available: www.cvdvaccine-us.com

^b Diluent: Sterile 0.9% Sodium Chloride Injection, USP. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent.

Regardless of storage condition, vaccines should not be used after 9 months from the date of manufacture printed on the vial and cartons.

The vaccine is currently under emergency use authorization review by the Food and Drug Administration (FDA) for children 6 months through 4 years old.

Pfizer Training – now includes Maroon Cap info!

Pfizer Vaccines US Medical Affairs hosts **frequent** Medical Updates & Immunization Site Training for All Healthcare Providers.

In addition to medical updates, sessions will focus on vaccine storage, handling, and administration of vaccines all vaccine formulations. These sessions will be updated to reflect new information and changes that evolve. Updates will be identified at the start of each session and explained during each presentation.

For a list of training sessions, including links and instructions for registration, visit the

Pfizer training website

https://www.pfizermedicalinformation.com/en-us/medical-updates

Recent Provider Outreach

- There will be a heavy dependency on the Medical Home for administration
 - Start thinking about how you want to vaccinate this population.
 - Please reach out to us if you are concerned.
- Immunization Program has been contacting practices the last few days to assess plans and offer assistance
 - Making efforts to speak with every practice that sees more than 500 kids in this age range.
 - Calls have been overwhelmingly positive.
 - Purpose of calls was to assess planning and offer support where needed.
 - All practices that see ANY kids in this age range should make attempts to carry this vaccine.
 - Future outreach is planned for smaller offices.

What can the Immunization Program do to help you?

Mailing from Immunization Program





Vermont Chapter

INCORPORATED IN VERMONT



What Families with Children Should Know About COVID-19 Vaccines

Every VAVP/VCVP enrolled office will receive a mailing in the coming weeks.

- One or two large posters for placement in your entrance or waiting room to every office. <u>COVID19</u>-<u>AskVaccinePoster11x17</u>
- A batch of handouts designed for parents and caregivers who may be hesitant for their child to receive the vaccine (VCVP enrolled only). <u>COVID-19</u> <u>Vaccine in Children - Parent Handout</u>

Translated links to both documents will be available on the <u>COVID-19</u>
<u>Translations | Vermont Department of Health</u> webpage



AAP Grant Extension!



- Extension of monetary cap per practice up to \$10,000 (from \$5,000)
- Will apply to COVID-19 or Flu clinics held through the end of 2022
- http://www.aapvt.org/news/aapvt-chapter-still-accepting-grant-applications-flu-and-covid-19-vaccines
- If would like to apply for the grant, please complete the application (either in word or pdf form) and email back to Birdie Pauley at <u>BPauley@vtmd.org</u>

Immunization Communication

- Ordering guidance comes from <u>AHS.VDHCovidVaxDistribution@vermont.gov</u> prior to ordering on Wednesday.
- <u>Vaccine Information for Health Care Professionals</u> | <u>Vermont Department of Health</u> for links to provider updates, recent communications, and recorded meetings
 - Immunization Program 01/25/2022 Provider Call
 - Video: https://youtu.be/7z-XOckRuAQ
 - Slide deck: <u>www.healthvermont.gov/sites/default/files/documents/pdf/HS-IZ-VVP-</u>OfficeHours-01.25.2022.pdf

In case you missed it: slides 66-73 reposted here from presentation on 2/2/22


Practice Issues

Updated "Return to Play" Guidance

Dr. Jonathan Flyer – Division Chief Pediatric Cardiology, UVM Children's Hospital

Kristen Connolly, MD FAAP – Timber Lane Pediatrics





- .. <u>COVID-19 Interim Guidance: Return to Sports and Physical Activity (aap.org)</u>
- 2. <u>2022-01-21 RTP algorithm.pdf (aap.org)</u>

Home

News

COVID-19 Interim Guidance: Return to Sports and Physical Activity

Home / Critical Updates on COVID-19 / COVID-19 Interim Guidance / COVID-19 Interim Guidance: Return to Sports and Physical Activity

- Over the past year, the AAP has provided quarterly updates— and now after recent CDC isolation changes.
- Rates of myocarditis due to COVID remain low (0.5-3%).



General Teamwork Reminder: RTP

The Return-to-Play protocols based upon national recommendations to increase safety and minimize risk. Return-to-Play does not impact a student's ability to return to school. Return-to-Play should be a teams-based discussion between the parent and medical provider. Return-to-Play is not the responsibility of the school nurse.

Continued team-based care between school nurses and pediatric medical homes is encouraged. School nurses should advocate for families of students post-COVID-19 infection to communicate with their medical home before returning to activity.



AAP Algorithm

Severity of symptoms

Asymptomatic or mild

<4 days of fever > 100.4, <1 week of myalgia, chills, or lethargy

Assessment by Primary Care Physician (PCP) (phone, telemedicine, or in-person consultation)

Duringassessment:

- 1. Guidance re: duration of isolation
- 2.Do not exercise while in isolation
- 3. AHA 14-element screening evaluation, with special emphasis on symptoms of myocarditis (incidence: 0.5-3%):chest pain, shortness of breath (SOB) out of proportion to upper respiratory infection (URI) symptoms, new-onset-palpitations, or syncope

Negative AHA screen

Cleared to begin return to play (Box A) Positive AHA screen

In-office visit with complete physical exam (PE) (postisolation). In patients with symptoms that may involve the cardiac system, such as; chest pain, shortness of breath with exercise (not related to pulmonary issues), syncope, the PCP should have electrocardiogram (EKG) done and interpreted prior to clearance to return. Refer to pediatric cardiologist for abnormal EKG. Exclude from physical activity until cleared by cardiology then return to play (Box A)

Moderate

≥4 days of fever >100.4°F, ≥1 week of myalgia, chills, or lethargy, or a non-ICU hospital stay and no evidence of multisystem inflammatory syndrome in children (MIS-C).

In-person evaluation by PCP after symptom resolution and completion of isolation

During in-person evaluation:

- 1. Do not exercise until cleared by PCP
- 2. AHA 14-element screening evaluation, with special emphasis on chest pain, SOB out of proportion to URI symptoms, new-onset-palpitations, or syncope
- 3. Complete physical exam
- 4. EKG

Negative AHA screen, normal exam, and normal EKG Positive AHA screen, abnormal exam, or abnormal EKG

Refer to cardiology, exclude from physical activity until cleared by cardiology

Cleared to begin the return to play (Box A) after 10 days have passed from symptom onset or positive test

Severe

ICU stay and/or intubation, or MIS-C

Restrict from exercise for

3-6 months, obtain cardiology clearance prior to resuming training or competition

Recent AAP Updates



BOX A: Additional Guidance on Returning to Play (Note: if the patient has already advanced back to physical activity on their own and is without abnormal cardiovascular signs/symptoms, then no further evaluation is necessary. COVID19 disease history should be documented.)

When should children and adolescents return to play?

- Completed isolation and minimum amount of symptom free time has passed
- 2) Can perform all activities of daily living
- No concerning signs/symptoms
- Physician clearance has been given, if indicated

At what pace should children and adolescents return to play?

- <12yo: progress according to own tolerance
- 6) 12+: gradual return to physical activity



- Asymptomatic / Mild symptoms: Minimum 1 day symptom free (excluding loss of taste / smell), 2 days of increase in physical activity (i.e. one light practice, one normal practice), no games before day 3. A mask is required for ALL physical activity, including games or scrimmages, until 10 full days from + test or symptom onset have passed.
- Moderate symptoms: Minimum 1 day symptom free (excluding loss of taste / smell), and a minimum of 4 days of gradual increase in
 physical activity (one light cardio workout on own, two light practices, one full practice), no games before day 5. A mask is required for ALL
 physical activity, including games or scrimmages, until 10 full days from + test or symptom onset have passed.

When should children and adolescents pause return to play?

If patient develops any chest pain, SOB out of proportion to URI infection, new-onset palpitations, or syncope when returning to exercise, immediately stop
and go to PCP for in-person exam and consider referral to Pediatric Cardiology

Recent AAP Updates

Still the Same

- If the patient has already advanced to physical activity on their own and is without abnormal cardiovascular signs/symptoms, then no further evaluation is necessary → this is primarily intended for past illness.
- 2. COVID19 disease history should be documented.

Quick Hits!

Illness Category

- Asymptomatic/mild:
 - Does <u>not need in person</u> visit
 - Can be medically evaluated <u>after 5 days</u> of isolation
 - RTP is shorter (now 2 days instead of 7) and modified
- Moderate:
 - Can be medically evaluated <u>after 5 days</u> of isolation, + <u>in person exam and EKG</u>
 - RTP progression can start <u>after 10</u> days
 - RTP is shorter (now 4 days instead of 7) and modified (see Box A)

Age Category

- <12yrs: RTP as tolerated
- ≥ 12
- Asymptomatic/Mild: 2 day RTP
- Moderate: 4 day RTP

Parents/caregivers: Monitor RTP

American Academy of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN®

- 1. <u>COVID-19 Interim Guidance: Return to Sports and Physical</u>
 - Activity (aap.org)
- 2. 2022-01-21 RTP algorithm.pdf (aap.org)



General Practice

- 1 Document → Age Based |
 - 1. Guidance
 - 2. Screening

Paperwork

Workflow





Current as of February 1, 2022

MEDICAL GUIDELINE FOR RETURN-TO-PLAY AFTER COVID-19 INFECTION

tient Name:	DOB:
te of Positive COVID Test:	
te of Symptom Onset:	N/A if asymptomatic:
te of Last Symptoms:	N/A if asymptomatic: □
<12yo ASYMPTOMATIC/MILD	or MODERATE symptoms:
GUIDANCE	□ No exercise while in isolation
SCREENING	□ AHA 14-element screen reviewed and negative
□ RETURN TO PLA	AY:
May progress r	 physical activity according to own tolerance once out of isolation
	for ALL activity until 10 full days from +test or symptom onset has passed
	op activity and have in-person medical evaluation for any chest pain, shortness of breath out of
	h symptoms, new-onset palpitations, or syncope with return to exercise
12yo ASYMPTOMATIC/MILD	symptoms week myalgia, chills, or lethargy)
GUIDANCE	□ No exercise while in isolation
SCREENING	□ AHA 14-element screen reviewed and negative
SCREENING	□ Out of isolation and >1 day symptom-free (excluding loss of taste/smell)
□ RETURN TO PLA	
	ys of increase in physical activity (ie. one light practice, one normal practice)
• IVIIIIIIIIII 2 ua	ys of increase in physical activity (ie. one light practice, one normal practice)
 No games before 	
No games befo	ore day 3
 Mask required 	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed
Mask required Immediately st	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of
Mask required Immediately st	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed
Mask required Immediately st proportion with	ore day 3 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of th symptoms, new-onset palpitations, or syncope with return to exercise
Mask required Immediately st proportion with 212yo MODERATE symptoms	ore day 3 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of h symptoms, new-onset palpitations, or syncope with return to exercise
Mask required Immediately st proportion with 212yo MODERATE symptoms (24 days fever >100.4, 21 w	ore day 3 for ALL activity until 10 full days from +test or symptom onset has passed sop activity and have in-person medical evaluation for any chest pain, shortness of breath out of h symptoms, new-onset palpitations, or syncope with return to exercise week of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C)
Mask required Immediately st proportion with 212yo MODERATE symptoms	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed sop activity and have in-person medical evaluation for any chest pain, shortness of breath out of h symptoms, new-onset palpitations, or syncope with return to exercise week of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise while in isolation
Mask required Immediately st proportion with ≥12yo MODERATE symptoms (≥4 days fever >100.4, ≥1 w GUIDANCE	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of the symptoms, new-onset palpitations, or syncope with return to exercise veek of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise while in isolation No exercise until cleared by PCP
Mask required Immediately st proportion with 212yo MODERATE symptoms (24 days fever >100.4, 21 w	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of the symptoms, new-onset palpitations, or syncope with return to exercise veek of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise while in isolation No exercise until cleared by PCP In-person evaluation by PCP after symptoms resolved and out of isolation
Mask required Immediately st proportion with 212yo MODERATE symptoms (>4 days fever >100.4, ≥1 w GUIDANCE	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of h symptoms, new-onset palpitations, or syncope with return to exercise veek of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise while in isolation No exercise until cleared by PCP In-person evaluation by PCP after symptoms resolved and out of isolation Normal physical exam, AHA 14-element screen, and EKG
Mask required Immediately st proportion witl 212yo MODERATE symptoms (≥4 days fever >100.4, ≥1 w GUIDANCE SCREENING	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of h symptoms, new-onset palpitations, or syncope with return to exercise veek of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise while in isolation No exercise until cleared by PCP In-person evaluation by PCP after symptoms resolved and out of isolation Normal physical exam, AHA 14-element screen, and EKG ≥10 days have passed since symptom onset or positive test
Mask required Immediately st proportion with ≥12yo MODERATE symptoms (≥4 days fever >100.4, ≥1 w GUIDANCE SCREENING RETURN TO PL	veek of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise until cleared by PCP In-person evaluation by PCP after symptoms resolved and out of isolation Normal physical exam, AHA 14-element screen, and EKG > 10 days have passed since symptom onset or positive test AY:
Mask required Immediately st proportion with 212yo MODERATE symptoms (>4 days fever >100.4, >1 w GUIDANCE SCREENING RETURN TO PL Minimum 4 day	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of th symptoms, new-onset palpitations, or syncope with return to exercise week of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise while in isolation No exercise until cleared by PCP In-person evaluation by PCP after symptoms resolved and out of isolation Normal physical exam, AHA 14-element screen, and EKG ≥10 days have passed since symptom onset or positive test AY: ys of gradual increase in physical activity
Mask required Immediately st proportion with 212yo MODERATE symptoms (≥4 days fever >100.4, ≥1 w GUIDANCE SCREENING RETURN TO PL Minimum 4 day (ie. one light ca	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of th symptoms, new-onset palpitations, or syncope with return to exercise veek of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise while in isolation No exercise until cleared by PCP In-person evaluation by PCP after symptoms resolved and out of isolation Normal physical exam, AHA 14-element screen, and EKG >10 days have passed since symptom onset or positive test AY: ys of gradual increase in physical activity ardio workout, two light practices, one full practice)
Mask required Immediately st proportion with 212yo MODERATE symptoms (24 days fever >100.4, ≥1 w GUIDANCE SCREENING RETURN TO PL Minimum 4 day (ie. one light ca No games befo	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of th symptoms, new-onset palpitations, or syncope with return to exercise week of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise while in isolation No exercise until cleared by PCP In-person evaluation by PCP after symptoms resolved and out of isolation Normal physical exam, AHA 14-element screen, and EKG >10 days have passed since symptom onset or positive test AY: ys of gradual increase in physical activity ardio workout, two light practices, one full practice) ore day 5
Mask required Immediately st proportion with 212yo MODERATE symptoms (>4 days fever >100.4, ≥1 w GUIDANCE SCREENING RETURN TO PL Minimum 4 day (ie. one light ca No games befo Mask required	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of h symptoms, new-onset palpitations, or syncope with return to exercise veek of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise while in isolation No exercise until cleared by PCP In-person evaluation by PCP after symptoms resolved and out of isolation Normal physical exam, AHA 14-element screen, and EKG >10 days have passed since symptom onset or positive test AY: ys of gradual increase in physical activity ardio workout, two light practices, one full practice) ore day 5 for ALL activity until 10 full days from +test or symptom onset has passed
Mask required Immediately st proportion with 212yo MODERATE symptoms (>4 days fever >100.4, ≥1 w GUIDANCE SCREENING RETURN TO PL Minimum 4 day (ie. one light ca No games befo Mask required	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of th symptoms, new-onset palpitations, or syncope with return to exercise week of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise while in isolation No exercise until cleared by PCP In-person evaluation by PCP after symptoms resolved and out of isolation Normal physical exam, AHA 14-element screen, and EKG >10 days have passed since symptom onset or positive test AY: ys of gradual increase in physical activity ardio workout, two light practices, one full practice) ore day 5
Mask required Immediately st proportion with ≥12yo MODERATE symptoms (≥4 days fever >100.4, ≥1 w GUIDANCE SCREENING RETURN TO PL Minimum 4 day (ie. one light ca No games befo Mask required Immediately st	re day 3 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of h symptoms, new-onset palpitations, or syncope with return to exercise veek of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise while in isolation No exercise until cleared by PCP In-person evaluation by PCP after symptoms resolved and out of isolation Normal physical exam, AHA 14-element screen, and EKG >10 days have passed since symptom onset or positive test AY: ys of gradual increase in physical activity ardio workout, two light practices, one full practice) ore day 5 for ALL activity until 10 full days from +test or symptom onset has passed
Mask required Immediately st proportion with ≥12yo MODERATE symptoms (≥4 days fever >100.4, ≥1 w GUIDANCE SCREENING RETURN TO PL Minimum 4 day (ie. one light ca No games befo Mask required Immediately st	for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of h symptoms, new-onset palpitations, or syncope with return to exercise veek of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise while in isolation No exercise while in isolation No exercise until cleared by PCP In-person evaluation by PCP after symptoms resolved and out of isolation Normal physical exam, AHA 14-element screen, and EKG >10 days have passed since symptom onset or positive test AY: ys of gradual increase in physical activity ardio workout, two light practices, one full practice) ore day 5 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of
Mask required Immediately st proportion with ≥12yo MODERATE symptoms (≥4 days fever >100.4, ≥1 w GUIDANCE SCREENING RETURN TO PL Minimum 4 day (ie. one light ca No games befo Mask required Immediately st	for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of h symptoms, new-onset palpitations, or syncope with return to exercise veek of myalgia, chills, or lethargy, or non-ICU hospital stay without evidence of MIS-C) No exercise while in isolation No exercise while in isolation No exercise until cleared by PCP In-person evaluation by PCP after symptoms resolved and out of isolation Normal physical exam, AHA 14-element screen, and EKG >10 days have passed since symptom onset or positive test AY: ys of gradual increase in physical activity ardio workout, two light practices, one full practice) ore day 5 for ALL activity until 10 full days from +test or symptom onset has passed top activity and have in-person medical evaluation for any chest pain, shortness of breath out of

14-Element AHA Screening Checklist

1	
Screen	ning
1.	Bolded
2.	Non-bolded

YesNo	
	Chest pain/tightness/pressure related to exertion
	Unexplained syncope or near-syncope (not including vasovagal cause)
	Excessive exertional, unexplained shortness of breath/fatigue or new onset palpitations with exercise
	New heart murmur on exam or persistent tachycardia
	Abnormal pulses on exam including femoral pulses (to exclude aortic coarctation)
	History of elevated systemic blood pressure
	Prior restriction from participation in sports
	Prior cardiac testing ordered by a physician
	Family history of premature death <50yrs due to heart disease
	Disability due to heart disease in a close relative <50yo
	Family history of HCM/Dilated cardiomyopathy, long QT/ion channelopathies, Marfan syndrome, significant arrhythmias, or genetic cardiac conditions
	History of heart murmur (excluding innocent/resolved murmurs)
	Physical stigmata of Marfan Syndrome
	Abnormal brachial artery blood pressure in sitting position on exam


14-Element AHA Screening Checklist adapted from Maron BJ, et al. Journal of the American College of Cardiology, 2014. AHA 14-element screening to be reviewed with special emphasis on symptoms of myocarditis (incidence 0.5-3%): chest pain, shortness of breath out of proportion with URI symptoms, new-onset palpitations, or syncope. Positive screening on non-bolded elements of the checklist may prompt cardiology referral, however these concerns are unlikely to be related to COVID19.



In case you missed it...

FINAL Updated Pediatric Flow Chart

- Posted on VCHIP & AAPVT web sites with live links
- □ Thank you:
 - Stephanie Winters
 - Rebecca Bell
 - Breena Holmes
 - VDH partners: Kaitlyn Kodzis, Katy Leffel, Molly McClintock, Ilisa Stalberg, Nate Waite





From the VDH MCH School Health Team

Thank you, Kaitlyn Kodzis - January School Nurse Bulletin: Contents

- Vermont COVID-19 Information
- Test at Home Protocol
- □ COVID-19 Prevention & Mitigation Measures Winter 2022
- COVID-19 School Testing Program FAQs
- Mental Health Resources
- Publications
- Nurses in the News





NEW from VDH Oral Health Office

- Newly updated <u>2021 Guide to Fluoride Levels in Public Water Systems</u>; enables health care professionals to determine level of fluoride in patient's public water system before Rx for fluoride supplements. Does NOT include fluoride levels of private wells or springs; DOES include info re: private water source testing. Hard copies may be requested for practices.
- VDH recommends Vermonters w/private wells or springs test water for fluoride levels before getting Rx for fluoride supplements.
 - Impt. to test since exposure can occur through mixing tap water w/infant formula & drinking well or spring water.
 - Well Water Testing Program offers free fluoride testing for families with children < 5 yo w/private wells. Guide includes. well water testing form (pls make copies for office use).</p>
- Testing Program tracks # of requests vs. # of wells tested; many more kits are given out then are returned/processed by the lab (risks funding loss).

Black History Month Education Resources (Families/Teachers)

- I HAVE A DREAM
 VISION BOARD
 VINNEY
 VI
- □ *Thank you, Melissa Kaufold!* https://www.vermontpbs.org/kids-education/?ct=t(BLACK-HISTORY-MONTH-PROGRAMMING-20220201)
- VPR & Vermont PBS: films, activities & lessons to deepen children's understanding of Black history. Free to families and teachers; support at-home or classroom learning for children of all ages.
- Young children: includes the "I have a dream" vision board activity from PBS Parents and PBS Learning Media.
- Middle school: VPR's *Timeline* podcast (Great Migration to Chicago/Harlem). 2/17 VT PBS to broadcast *Legacy of Love* (MLK & Coretta Scott's formative years in 1950's Boston).
- HS students/adults: 2/8 VT PBS to broadcast *Marian Anderson: The Whole World in Her Hands*. 2/10 Made Here will air *The Price of Safety*, which explores conversations of over-policing & racial bias in Vergennes, VT. 2/15 *The American Diplomat*: how three Black diplomats broke racial barriers at the U.S. State Dept.

during the Cold War. February 9, 2022

VCHIP-VDH COVID-19 calls - 2022!

February calls: currently all Wednesdays:

- □ 2/2, 2/9, 2/16, 2/23/22
- We recognize that February school vacation weeks may affect your ability to participate!
- Continuing via Zoom!
- Schedule subject to change at any time if circumstances warrant!
- Please continue to send your feedback re: schedule/topics to vchip.champ@med.uvm.edu
- □ VMS calls w/VDH Comm. Levine now 1st/3rd Thursdays







VCHIP-VDH COVID-19 Update Calls – now via **ZOOM**!

Call login information:

- □ Topic: CHAMP VDH COVID-19 Call
- Join Zoom Meeting
 - https://uvmcom.zoom.us/j/94142791300?pwd=K2N4VUYrSHIMQi9XeGVnc3duNTFmZz09
 - NOTE: password (CHAMP) should be imbedded in link (sharing in case needed for any reason. You will not be prompted to enter PW if using link we provided.
- Meeting ID: 941 4279 1300
- Passcode: CHAMP
- One tap mobile
- +16468769923,,94142791300# US (New York)
- □ +13017158592,,94142791300# US (Washington DC)





Questions/Discussion

- □ Q & A Goal: monitor/respond in real time; record/disseminate/revisit later as needed.
- □ For additional questions, please e-mail: vchip.champ@med.uvm.edu
 - What do <u>you</u> need how can we be helpful (specific guidance)?
- □ VCHIP CHAMP VDH COVID-19 website:

 https://www.med.uvm.edu/vchip/projects/vchip_champ_vdh_covid-19_updates
- Next CHAMP call Wednesday, February 16, 2022 12:15 1:00 pm VIA ZOOM!
- Please tune in to VMS COVID-19 call with VDH Commissioner Levine Thursday,
 February 17 12:30-1:00 p.m.
- □ Join VMS Zoom Meeting:

https://us02web.zoom.us/j/86726253105?pwd=VkVuNTJ1ZFQ2R3diSVdqdlJ2ZG4yQT09

- Meeting ID: 867 2625 3105 / Password: 540684
- One tap mobile +1 646 876 9923,,86726253105#,,,,0#,,540684#



